MDxHealth SA, a precision diagnostics company, has announced the completion of its acquisition of Exosome Diagnostics from Bio-Techne Corporation. This acquisition includes the ExoDx Prostate test and related assets, with a total consideration of $15 million. The payment structure involves $5 million in stock at closing, followed by $2.5 million annually over the next four years, with 50% in cash and the remainder at mdxhealth's discretion in cash or stock.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MDxHealth SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001128148-en) on September 15, 2025, and is solely responsible for the information contained therein.